I have a 4-year-old intact female Mini Lop rabbit present...

Thank you for reaching out regarding this challenging case. A high-grade uterine adenocarcinoma in a 4-year-old Mini Lop is certainly a significant diagnosis, and I commend the prompt ovariohysterectomy. Uterine adenocarcinoma is the most common neoplasia in intact female rabbits, and unfortunately, it carries a high metastatic potential, particularly to the lungs, with reported rates ranging from 50-90% at the time of diagnosis or within a year post-surgery. The high-grade classification further underscores this aggressive behavior.

Given the histopathology confirming high-grade adenocarcinoma, adjuvant therapy to mitigate metastatic risk is a very appropriate consideration. While robust, evidence-based chemotherapy protocols for rabbits are not as extensive as for dogs and cats, we can extrapolate from principles of oncology and limited published data in exotic species. The goal, as always, is to balance potential efficacy with maintaining an excellent quality of life for the patient.

Let's discuss metronomic chemotherapy, specifically cyclophosphamide and piroxicam, as requested:

Metronomic Cyclophosphamide:

* Rationale: Metronomic chemotherapy, involving low-dose, continuous administration, aims to target the tumor microenvironment by inhibiting angiogenesis and modulating the immune response, rather than directly killing tumor cells in a cytotoxic fashion. For high-grade carcinomas with potential for micrometastatic disease, this approach can be appealing for its generally lower acute toxicity profile compared to traditional cytotoxic doses.
* Dosing & Monitoring (Extrapolation): While a verified rabbit-specific metronomic dose for cyclophosphamide is not in our standard formulary, for dogs, the metronomic dose is typically cyclophosphamide 10-15 mg/m²/day PO. For a rabbit, this would be a significant extrapolation and would require extreme caution. A more conservative approach often starts with a lower dose, perhaps 5-10 mg/m² every other day or a few times a week, and careful upward titration.
* Side Effects: The primary concerns with cyclophosphamide are myelosuppression (neutropenia) and sterile hemorrhagic cystitis. In rabbits, gastrointestinal stasis is a paramount concern with any systemic medication, and cyclophosphamide can exacerbate this.
* Monitoring: Regular CBCs (every 1-2 weeks initially, then monthly) are essential to monitor for myelosuppression. Urinalysis should be performed periodically to check for sterile hemorrhagic cystitis, and concurrent furosemide (if tolerated) or encouraging high water intake can help. Close monitoring of appetite, fecal output, and general demeanor is critical for GI stasis.

Piroxicam:

* Rationale: Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), has demonstrated anti-tumor effects in various carcinomas, including TCC, mammary carcinoma, and some sarcomas, primarily through its inhibition of COX-2 pathways which are often overexpressed in tumors. It can reduce tumor growth, angiogenesis, and metastasis.
* Dosing & Monitoring (Extrapolation): Again, a specific metronomic rabbit dose for piroxicam is not in our standard formulary. In dogs, the dose is piroxicam 0.3 mg/kg PO Daily. However, NSAID use in rabbits is associated with a much higher risk of gastrointestinal ulceration and renal toxicity compared to dogs.
* Side Effects: The most significant risks in rabbits are severe GI ulceration, renal injury, and hepatic enzyme elevation.
* Monitoring: If considering piroxicam, it would need to be initiated at a very low dose, potentially every 48-72 hours, with concurrent gastroprotectants (e.g., sucralfate, omeprazole) and meticulous monitoring of appetite, fecal output, and bloodwork (renal values, liver enzymes, CBC). I would advise extreme caution with continuous piroxicam in a rabbit due to the species' sensitivity to NSAIDs.

General Considerations for Adjuvant Therapy in Rabbits:

* Evidence Gap: It is crucial to emphasize that the efficacy of these specific metronomic protocols for rabbit uterine adenocarcinoma is largely anecdotal or extrapolated from other species. There is a significant lack of prospective clinical trials.
* Alternative Chemotherapy: While not specifically asked, single-agent doxorubicin or carboplatin could be considered in a more traditional cytotoxic protocol, but again, rabbit-specific protocols are not well-established. Doxorubicin has cardiac and renal toxicities in other species, and carboplatin is myelosuppressive; these would need careful consideration and monitoring in a rabbit.
* Staging: Post-operative thoracic radiographs (3 views) are essential to screen for macroscopic pulmonary metastases. Given the high metastatic rate, these should be performed. If clear, adjuvant therapy is aimed at micrometastatic disease. If pulmonary metastases are already present, the prognosis is significantly poorer, and therapy would be palliative.
* Quality of Life: Rabbits are highly sensitive to stress and illness. Any adjuvant protocol must prioritize maintaining excellent quality of life. Frequent veterinary visits for monitoring, potential side effects, and the stress of medication administration must be carefully weighed against the potential benefits.
* Nutritional Support & GI Motility: Proactive management of GI motility with prokinetics (e.g., cisapride) and appetite stimulants (e.g., mirtazapine 1.88 mg/dog PO Daily, extrapolated very cautiously for a rabbit, or capromorelin) may be necessary if anorexia or GI stasis develops.
* Pain Management: Ensure multimodal pain management is in place, especially post-surgically and if any side effects arise.

Recommendation:

Given the high-grade nature and the known aggressive behavior of rabbit uterine adenocarcinoma, an adjuvant metronomic chemotherapy protocol is a reasonable consideration, despite the limitations in species-specific data.

My preferred approach would be to consider metronomic cyclophosphamide as a primary option, starting at a conservative dose (e.g., 5-10 mg/m² orally, 3 times a week, or every other day) and gradually increasing frequency or dose as tolerated, with very close hematologic monitoring (CBC every 1-2 weeks initially). This would be paired with proactive measures to prevent hemorrhagic cystitis and vigilant monitoring for GI stasis.

I would be very cautious with piroxicam due to the high risk of GI and renal toxicity in rabbits. If used, it would need to be at a very low dose (e.g., 0.1-0.2 mg/kg PO every 48-72 hours) with concurrent gastroprotectants, and only if cyclophosphamide is not tolerated or if there's a strong rationale for its specific anti-inflammatory/anti-tumor effects in this individual.

Before initiating any protocol, I would strongly recommend a full discussion with the owner about the lack of definitive data, the potential side effects, the financial commitment, and the primary goal of extending good quality life. Regular follow-up thoracic radiographs (e.g., every 2-3 months) would be crucial to monitor for pulmonary metastasis.

This is a scenario where collaboration with an exotic animal specialist who has experience with oncology in rabbits would be highly beneficial, as they can provide species-specific insights into drug tolerance and supportive care.